Fig. 7.
CGI-58 ASO treatment increases hepatic ceramide content in the lipid droplet/ER and membrane. (A) Hepatic ceramide concentrations as assessed by LC/MS/MS in mice treated with control or CGI-58 ASO for 8 wk (n = 8 per group). (B) Ceramide concentration in the lipid droplet/ER fraction. (C) Ceramide concentration in the cytoplasmic fraction. (D) Ceramide concentration in the membrane fraction (n = 6 per group). P value calculated by two-way ANOVA.
